Method of treating a liver disease comprising administering ostreolysin orfunctionally related variant thereof

Abstract

Disclosed are methods for treating, preventing and alleviating obesity, fatty liver syndrome, diabetes, one or more metabolic syndrome conditions or complications and/or cancer comprising administering an effective amount of ostreolysin, its functionally related variant, or an extract or mushroom extract comprising the same to subjects in need thereof.

1 . A method of treating obesity or overweight comprising the step of administering to a subject in need a formulation comprising a therapeutically effective amount of ostreolysin, or a functionally related variant of ostreolysin having at least 95% sequence identity to SEQ ID NO: 1. 
     
     
         2 . The method of  claim 1 , wherein the functionally related variant of ostreolysin has at least 99% sequence identity to SEQ ID NO:1. 
     
     
         3 . The method of  claim 1 , wherein the formulation is a pharmaceutical formulation. 
     
     
         4 . The method of  claim 1 , wherein the formulation is in the form of a powder, solution, enteric coated table, suspension, emulsion, tablet, capsule, enteric coated tablet, gel, cream, ointment, foam, paste or injection. 
     
     
         5 . The method of  claim 1 , wherein the ostreolysin is a recombinant protein. 
     
     
         6 . The method of  claim 1 , wherein the ostreolysin is a purified protein. 
     
     
         7 . The method of  claim 1 , wherein the therapeutically effective amount of ostreolysin is between 5-10 mg for a 60 kg individual. 
     
     
         8 . A method of enhancing production of brown fat adipocytes, or promoting brown adipocyte differentiation, the method comprising contacting a precursor of brown fat adipocytes with a composition comprising an effective amount of ostreolysin, or a functionally related variant of ostreolysin having at least 95% sequence identity to SEQ ID NO: 1, so as to enhance production of brown fat adipocytes or promote brown adipocyte differentiation. 
     
     
         9 . The method of  claim 7 , wherein the functionally related variant of ostreolysin has at least 99% sequence identity to SEQ ID NO:1. 
     
     
         10 . The method of  claim 7 , wherein the enhancing of production of brown fat adipocytes or promoting brown adipocyte differentiation is effective in treating overweight or obesity in a subject in need thereof. 
     
     
         11 . The method of  claim 7 , wherein the composition is in a form of a powder, solution, suspension, emulsion, tablet, enteric coated tablet, or capsule, gel, cream, ointment, foam, paste or injection. 
     
     
         12 . The method of  claim 7 , wherein the precursor of brown fat adipocytes is a stem cell, mesenchymal stem cell, myogenic precursor, brown pre-adipocyte and white pre-adipocyte. 
     
     
         13 . The method of  claim 7 , wherein the formulation is a pharmaceutical formulation. 
     
     
         14 . The method of  claim 7 , wherein the ostreolysin is a recombinant protein. 
     
     
         15 . The method of  claim 7 , wherein the ostreolysin is a purified protein. 
     
     
         16 . The method of  claim 7 , wherein the therapeutically effective amount of OLY is between 5-10 mg for a 60 kg individual.